KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Liabilities: 2009-2025

Historic Total Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Sep 2025 value amounting to $4.6 billion.

  • Alnylam Pharmaceuticals' Total Liabilities rose 10.67% to $4.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year increase of 10.67%. This contributed to the annual value of $4.2 billion for FY2024, which is 3.02% up from last year.
  • Alnylam Pharmaceuticals' Total Liabilities amounted to $4.6 billion in Q3 2025, which was up 7.01% from $4.3 billion recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Total Liabilities registered a high of $4.6 billion during Q3 2025, and its lowest value of $2.3 billion during Q1 2021.
  • Moreover, its 3-year median value for Total Liabilities was $4.1 billion (2023), whereas its average is $4.1 billion.
  • Data for Alnylam Pharmaceuticals' Total Liabilities shows a peak YoY soared of 150.47% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' Total Liabilities stood at $3.1 billion in 2021, then climbed by 21.26% to $3.7 billion in 2022, then grew by 9.34% to $4.1 billion in 2023, then climbed by 3.02% to $4.2 billion in 2024, then increased by 10.67% to $4.6 billion in 2025.
  • Its last three reported values are $4.6 billion in Q3 2025, $4.3 billion for Q2 2025, and $4.1 billion during Q1 2025.